The results from the heterozygote model comparison, dominant model comparison and allelic frequency comparison showed no evidence that the CTLA-4 -1661A/G polymorphism was significantly associated with an increased other cancers risk (GA vs. AA: OR = 1.57, 95%CI = 0.93–2.67; GA+GG vs. AA: OR = 1.13, 95%CI = 0.91–2.47; G vs. A: OR = 1.31, 95%CI = 0.91–1.88). Here, CTLA4 is linked to cancer.